EGFR and non-small cell lung carcinoma: In addition to the current study with dacomitinib, several clinical trials or retrospective studies have shown that other EGFR TKIs, including afatinib and dacomitinib, can improve clinical outcomes in EGFR‐mutated NSCLC with BMs.